Startseite
Kongressberichte 2021
63rd ASH Annual Meeting and Exposition In-Person/Virtual
Multiple Myeloma
Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological
Challenges in Multiple Myeloma Therapy: Adopting New Approaches for Relapse and Monitor
652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Challenges in Multiple Myeloma Therapy: Adopting New Approaches for Relapse and Monitor
Jonathan L. Kaufman, Hang Quach, Rachid Baz, et al.
A tolerable safety profile was observed in t t (11; 14) -selected RRMM patients who were treated with VenDd vs. DVd. Updated analyzes will be presented in the oral session.
Xiang Zhou1*, Andrej Besse2*, Jessica Peter, et al.
High-dose CFZ (≥ 36 mg / m2) achieved a more effective inhibition of the proteasome by blocking the β5 and β2 subunits. Inadequate inhibition of the β2 subunit was achieved with low-dose CFZ. The authors thus prove that high-dose CFZ could regain the response in RRMM patients - resistant to low-dose CFZ - by co-inhibiting the β2 subunit activity of the proteasome complex.
Sarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, et al.
See abstract for more info.
Hannah Victoria Giles, Mark T Drayson, Nicola Wright, et al.
See abstract for more info.
Tarek H. Mouhieddine, Oliver Van Oekelen, Darren Pan, et al.
See abstract for more info.
Oliver Van Oekelen, Sarita Agte, Adolfo Aleman, et al.
See abstract for more info.